More importantly, when compared with low STOML2 expression group, the significantly worse OS (median OS: 38.9 months versus more than 55 months, log-rank = 10.3, P = 0.001) (Fig. 1g) and shortened time to tumor recurrence (TTR) (median TTR: 22 months versus 53 months, log-rank = 8.7, P = 0.003) (Fig. 1h) were found in STOML2 high expression group. This evidence concerns the gene STOML2 and neoplasm.